Unity Biotechnology, Inc.
0.0561+0.00 (+0%)
Oct 14, 4:00:00 PM EDT · OTC Markets OTCPK · UNBX · USD
Key Stats
Market Cap
965.60KP/E (TTM)
-Basic EPS (TTM)
-1.63Dividend Yield
0%Recent Filings
8-K
Unity terminates lease, dissolves
Unity Biotechnology terminated its South San Francisco lease early, effective March 31, 2026, paying $3.65 million in prepaid rent to exit three years ahead. This cuts costs amid the biotech's full dissolution, approved by shareholders on September 18 and finalized September 26, 2025, closing transfer books. Yet, the landlord claims 25% of any asset monetization proceeds up to $26.9 million. Dissolution locks in the end.
8-K
Stockholders approve dissolution
Unity Biotechnology's stockholders overwhelmingly approved the company's liquidation and dissolution on September 18, 2025, with 450 million votes in favor against 151 million opposed, granting the board authority to wind down operations under the Plan of Dissolution. This caps a turbulent period marked by Nasdaq delisting in July 2025 and OTC trading since. The board holds discretion on timing and may abandon the plan if circumstances shift. Yet risks loom large in asset monetization.
8-K
Preferred stock issuance for dissolution vote
Unity Biotechnology issued one share of Series A Preferred Stock to its president Craig Jalbert for $1.00 on July 22, 2025, granting it 600 million votes solely on the upcoming dissolution proposal. This structure mirrors common stock votes, minimizing abstention impact while preserving majority approval. The board approved dissolution on June 27, 2025, to wind down operations. Yet stockholder approval remains uncertain.
8-K
Unity approves dissolution plan
Unity Biotechnology's board approved a plan of dissolution on June 27, 2025, to wind down operations after failing Nasdaq's listing standards, triggering suspension of trading on July 9. All directors and key executives resigned, with restructuring expert Craig Jalbert appointed as sole director and officer to oversee the process. Stockholders will vote on the proposal soon. No assurance exists of asset monetization yielding value for creditors or investors.
8-K
Nasdaq bid price deficiency notice
Unity Biotechnology received a Nasdaq notice on June 18, 2025, for its common stock's closing bid price lingering below $1.00 over 30 business days, breaching listing rules. No immediate trading halt follows; the company has until December 15, 2025, to lift the price above $1.00 for ten straight days. It already faces a separate stockholders' equity shortfall below $10 million and applied to shift to Nasdaq Capital Market on June 9. Delisting looms if unmet, yet Unity eyes fixes to stay listed.
IPO
Employees
Sector
Industry
ADVM
Adverum Biotechnologies, Inc.
4.23-0.03
ANVS
Annovis Bio, Inc.
2.20+0.10
IBRX
ImmunityBio, Inc.
2.42-0.16
KALA
KALA BIO, Inc.
0.80-0.03
KPRX
Kiora Pharmaceuticals, Inc.
2.53+0.08
NBY
NovaBay Pharmaceuticals, Inc.
1.20-0.06
OCS
Oculis Holding AG
21.55+0.55
OKYO
OKYO Pharma Limited
2.72+0.17
QURE
uniQure N.V.
70.59+0.59
UNCY
Unicycive Therapeutics, Inc.
4.80+0.08